{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:26Z","timestamp":1761630626812},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mnh.0b013e328356c551","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T16:34:44Z","timestamp":1344443684000},"page":"486-491","source":"Crossref","is-referenced-by-count":21,"title":["Strategies for combination therapy in hypertension"],"prefix":"10.1097","volume":"21","author":[{"given":"Alan H.","family":"Gradman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210205","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"R2-6-20210205","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension.","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R3-6-20210205","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1751-7176.2008.00015.x","article-title":"Vidt DG, for the ALLHAT collaborative research group. Blood pressure control by drug group in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"10","author":"Cushman","year":"2008","journal-title":"J Clin Hypertens"},{"key":"R4-6-20210205","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R5-6-20210205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1751-7176.2010.00360.x","article-title":"Rationale for triple combination therapy in the management of hypertension.","volume":"12","author":"Gradman","year":"2010","journal-title":"J Clin Hypertens"},{"key":"R6-6-20210205","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"R7-6-20210205","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effect of ACE inhibitors, calcium channel blockers, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists Collaboration.","volume":"356","author":"Neil","year":"2000","journal-title":"Lancet"},{"key":"R8-6-20210205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"ASH position paper: combination therapy in hypertension.","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"R9-6-20210205","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archinte.1994.00420070047005","article-title":"Antihypertensive therapy effectiveness of low-dose lisinopril-hydrochlorthiazide combination. A large multicenter study.","volume":"154","author":"Chrysant","year":"1994","journal-title":"Arch Intern Med"},{"key":"R10-6-20210205","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"R11-6-20210205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1751-7176.2009.00138.x","article-title":"Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy.","volume":"11","author":"Elliott","year":"2009","journal-title":"J Clin Hypertens"},{"key":"R12-6-20210205","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9149(96)00781-3","article-title":"Combined enalapril and felodipine extended release (ER) for systemic hypertension.","volume":"79","author":"Gradman","year":"1997","journal-title":"Am J Cardiol"},{"key":"R13-6-20210205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis.","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"key":"R14-6-20210205","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension A meta-analysis.","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"key":"R15-6-20210205","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"R16-6-20210205","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat different ss-adrenergic receptor blocker.","volume":"54","author":"Munzel","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R17-6-20210205","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R18-6-20210205","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"for the ACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"R19-6-20210205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"R20-6-20210205","first-page":"116","article-title":"Effects of treatment on morbidity in hypertension.","volume":"202","year":"1967","journal-title":"JAMA"},{"key":"R21-6-20210205","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/HYPERTENSIONAHA.110.164566","article-title":"Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet H","volume":"57","author":"Flack","year":"2011","journal-title":"ypertension"},{"key":"R23-6-20210205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","article-title":"Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.","volume":"54","author":"Calhoun","year":"2009","journal-title":"Hypertension"},{"key":"R24-6-20210205","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment - a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"key":"R25-6-20210205","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension.","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"R26-6-20210205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","article-title":"Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.","volume":"20","author":"Weir","year":"2007","journal-title":"Am J Hypertens"},{"key":"R27-6-20210205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"R28-6-20210205","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(04)16456-8","article-title":"Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.","volume":"363","author":"Weber","year":"2004","journal-title":"Lancet"},{"key":"R29-6-20210205","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.111.177592","article-title":"Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice.","volume":"58","author":"Corrao","year":"2011","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"R30-6-20210205","first-page":"A73","article-title":"Impact of initial combination therapy vs. monotherapy on major cardiovascular (CV) events, a matched cohort study.","volume":"13","author":"Gradman","year":"2011","journal-title":"J Clin Hypertens"},{"key":"R31-6-20210205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.amjcard.2010.05.006","article-title":"Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events.","volume":"106","author":"Chrysant","year":"2010","journal-title":"Am J Cardiol"}],"container-title":["Current Opinion in Nephrology & Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNH.0b013e328356c551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:29:08Z","timestamp":1620962948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041552-201209000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mnh.0b013e328356c551","relation":{},"ISSN":["1062-4821"],"issn-type":[{"value":"1062-4821","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}